Experimental Therapy: In Vitro Models

  • John D. Cowan
  • Daniel D. von Hoff
Part of the Developments in Oncology book series (DION, volume 46)

Abstract

Cytotoxic agents have a key role in the treatment of cancer. Unfortunately, the effectiveness of these agents is limited, and their effect on an individual patient’s tumor is frequently difficult to predict. In an effort to improve the therapeutic results of cytotoxic chemical therapy, attempts have been made to develop an in vitro system to predict drug sensitivity in man, much as bacterial culture and sensitivity techniques are used to tailor antibiotic use. Such a system would allow (1) the rapid screening of potential antineoplastic agents, which would aid in the development of promising clinical trials; and (2) the selection of an appropriate chemotherapeutic agent or agents for an individual patient’s tumor.

Keywords

Lymphoma Estrogen Oncol Interferon Cane 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Cline M. In vitro test systems for anticancer drugs. N Engl J Med 280: 955, 1969.PubMedGoogle Scholar
  2. 2.
    Eagle H, Foley GE. Cytotoxicity in human cell cultures as a primary screen for the detection of anti-tumor agents. Cancer Res 18: 1017–1025, 1958.PubMedGoogle Scholar
  3. 3.
    Dendy PP, Bozman G, Wheeler TK. In vitro screening test for malignant human tumors before chemotherapy. Lancet 2: 68–72, 1970.Google Scholar
  4. 4.
    Lickiss JN, Cane KA, Baikie AG. In vitro drug selection in antineoplastic chemotherapy. Eur J Cancer 10: 809–814, 1974.PubMedGoogle Scholar
  5. 5.
    Limburg H, Heck U. Chemotherapy in the treatment of advanced pelvic malignant disease with special reference to ovarian cancer. J Obstet Gynecol Br Comm 75: 1246–1255, 1974.Google Scholar
  6. 6.
    Wright JC, Cobb JP, Gunport SL, Safad D, Walker DA, Golomb FM. Further investigation of the relation between the clinical and tissue culture response to chemotherapeutic agents on human cancer. Cancer 15: 284–293, 1962.PubMedGoogle Scholar
  7. 7.
    Lazarus H, Tegeler W, Mazzone HM, Leroy JG, Boone BA, Foley GE. Determination of sensitivity of individual biopsy specimens to potential inhibitory agents: Evaluation of some explant culture methods as assay systems. Cancer Chemother Rep 50: 543–555, 1966.PubMedGoogle Scholar
  8. 8.
    Beeby DI, Easty GC, Gazet JC, Grigor K, Neville A. An assessment of the effects of hormones on short term organ cultures of human breast carcinomata. Br J Cancer 31: 317–327, 1975.PubMedGoogle Scholar
  9. 9.
    Morasca L. Organ culture. In Human Tumors in Short Term Culture, Dendy PP (ed.). New York: Academic Press, 1976, pp. 33–35.Google Scholar
  10. 10.
    Abaza NA, Leighton S, Zajac BA. Clinical bladder cancer in sponge matrix tissue culture. Cancer 42: 1364–1374, 1978.PubMedGoogle Scholar
  11. 11.
    Saez RJ, Campbell RJ, Laws ER. Chemotherapeutic trials on human malignant astrocytomas in organ culture. J Neurosurg 46: 320–327, 1977.PubMedGoogle Scholar
  12. 12.
    Hurley J, Yount L. Selection of anticancer drug for palliation using tissue culture sensitivity studies. Am J Surg 109: 39–42, 1965.PubMedGoogle Scholar
  13. 13.
    Hittleman WN, Rao PN. Predicting response or progression of human leukemia by premature chromosome condensation of bone marrow cells. Cancer Res 38: 416–422, 1978.Google Scholar
  14. 14.
    Holmes HL, Little JM. Tissue culture microtest for predicting response of human cancer to chemotherapy. Lancet 2: 985–987, 1974.PubMedGoogle Scholar
  15. 15.
    Kornblith PL, Smith BH, Leonard LA. Response of cultured human brain tumors to nitrosoureas: Correlation with clinical data. Cancer 47: 255–265, 1981.PubMedGoogle Scholar
  16. 16.
    Hoskins JM, Meynell GG, Sanders FK. A comparison of methods for estimating the viable count of a suspension of tumor cells. Exp Cell Res 11: 297–305, 1956.PubMedGoogle Scholar
  17. 17.
    Durkin WJ, Ghanta VK, Balch CM, Davis DW, Hiramoto RM. A methodological approach to the prediction of anticancer drug effect in humans. Cancer Res 39: 402–407, 1978.Google Scholar
  18. 18.
    Tsukeda H, Mizuno S, Nitta K. Susceptibilities of normal and malignant human lung cells in culture to the cytocidal action of antitumor agents. Cancer Res 38: 2529–2532, 1978.PubMedGoogle Scholar
  19. 19.
    Graff JP, Blakley RL. Rescue of human lymphoid cells from the effects of methotrexate in vitro. Cancer Res 38: 3847–3853, 1978.Google Scholar
  20. 20.
    Burke RE, Mira JG, Datta R, Zava DT, McGuire WL. Estrogen action following irradiation of human breast cancer cells. Cancer Res 38: 2813–2817, 1978.PubMedGoogle Scholar
  21. 21.
    Grunwald HW, Rosner F, Hirshaut Y. Two dimensional view of combination chemotherapy in vitro. Am J Hematol 4: 35–46, 1978.PubMedGoogle Scholar
  22. 22.
    Yates J, King RJB. Multiple sensitivities of mammary tumor cells in culture. Cancer Res 38: 4135–4137, 1978.PubMedGoogle Scholar
  23. 23.
    Bhuyan BK, Loughman BE, Frazer TJ, Day KJ. Comparison of different methods of determining cell viability after exposure to cytotoxic compounds. Exp Cells Res 97: 275–280, 1976.Google Scholar
  24. 24.
    Roper P, Drewlinko B. Comparison of in vitro methods to determine drug induced cell lethality. Cancer Res 36: 2182–2188, 1976.PubMedGoogle Scholar
  25. 25.
    Weisenthal LM, Marsden J. A novel dye exclusion assay for predicting response to cancer chemotherapy. Proc Am Assoc Cancer Res and ASCO 22: 155, 1981.Google Scholar
  26. 26.
    Von Hoff DD, Weisenthal LM. In vitro methods to predict for patient response to chemotherapy. Adv Pharm Chemother 17: 133–156, 1980.Google Scholar
  27. 27.
    Weisenthal LM, Lippman ME. Clonogenic and nonclonogenic in vitro chemosensitivity assays. Cancer Treat Rep 69: 615–632, 1985.PubMedGoogle Scholar
  28. 28.
    Ronai P. The elution of 51Cr from labeled leukocytes—a new theory. Blood 33: 408–413, 1969.PubMedGoogle Scholar
  29. 29.
    Dickson JA, Suzge M. In vitro sensitivity testing of human tumor slices to chemotherapeutic agents—its place in cancer therapy. In Human Tumors in Short Term Culture, Dendy PP (ed.). New York: Academic Press. 1976, pp. 107–138.Google Scholar
  30. 30.
    Knock FE, Galt RM, Oester YT, Sylvester R. In vitro estimate of sensitivity of individual human tumors to antitumor agents. Oncology 30: 1–20, 1974.PubMedGoogle Scholar
  31. 31.
    Black MM, Speer FD. Further observations on the effects of cancer chemotherapeutic agents on the in vitro dehydrogenase activity of cancer tissue. J Natl Cancer Inst 14: 1147–1158, 1954.PubMedGoogle Scholar
  32. 32.
    DiPaola JA. Analysis of an individual chemotherapy assay system. Natl Cancer Inst Monogr 34: 240–245, 1971.Google Scholar
  33. 33.
    Kondo T. Prediction of response of tumor and host to cancer chemotherapy. Natl Cancer Inst Monogr 34: 251–256, 1971.PubMedGoogle Scholar
  34. 34.
    Twentyman PR. Sensitivity to l-3-bis(2-chloroethyl)-1-nitrosourea and 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea of the EMTG tumor in vivo as determined by both tumor volume and response and in vitro plating assay. Cancer Res 38: 2395–2400, 1978.PubMedGoogle Scholar
  35. 35.
    Wolberg WH. Determinants of human tumor sensitivity to fluorinated pyrimidine chemotherapy. Ann Surg 166: 609–623, 1967.PubMedGoogle Scholar
  36. 36.
    Hryniuk W, Bertino J. Treatment of leukemia with large doses of methotrexate and folinic acid: Clinical-biochemical correlates. J Clin Invest 48: 2140–2155, 1969.PubMedGoogle Scholar
  37. 37.
    Momparler RL. Kinetic and template studies with l-β-D-arabinofuranosylcytosine-5′-triphosphatase and mammalian deoxyribonucleic acid polymerase. Mol Pharmacol 8: 362–370, 1972.PubMedGoogle Scholar
  38. 38.
    Capizzi RL, Bertino JR, Steel RT. L-asparaginase: Clinical, biochemical, pharmacological and immunological studies. Ann Intern Med 24: 893–901, 1971.Google Scholar
  39. 39.
    McGuire WL. Hormone receptors: Their role in predicting prognosis and response to endocrine therapy. Semin Oncol 5: 428–433, 1978.PubMedGoogle Scholar
  40. 40.
    Lippman ME, Allegra JC. Receptors in breast cancer. N Engl J Med 299: 930–933, 1978.PubMedGoogle Scholar
  41. 41.
    Wolberg WH. Biochemical approaches to prediction of response in solid tumors. Natl Cancer Inst Monogr 34: 189–195, 1971.PubMedGoogle Scholar
  42. 42.
    Smyth JF, Robins AB, Leese CL. The metabolism of cytosine arabinoside as a predictive test for clinical response to the drug in acute myeloid leukemia. Eur J Cancer 12: 567–573, 1976.PubMedGoogle Scholar
  43. 43.
    Chang P, Wiernik P, Bachur N, Stoller R, Chabner B. Failure to predict response of acute non-lymphocytic leukemia using assays for deoxycytidine kinase, cytidine deaminase and daunorubicin reductase. Proc Am Assoc Cancer Res and ASCO 18: 352, 1977.Google Scholar
  44. 44.
    Kessel D, Hall T. Retention of 6-mercaptopurine derivatives by intact cells as an index of drug response in human and murine leukemias. Cancer Res 29: 2116–2119, 1969.PubMedGoogle Scholar
  45. 45.
    Kessel D. Relevance of in vitro tests for predicting responsiveness to antitumor agents. Natl Cancer Inst Monogr 34: 138–145, 1971.PubMedGoogle Scholar
  46. 46.
    Bender RA, Bleyer WA, Drake JC, Ziegler JL. In vitro correlations of clinical response to methotrexate in acute leukemia and Burkitt’s lymphoma. Br J Cancer 34: 484–492, 1976.PubMedGoogle Scholar
  47. 47.
    Cline M, Rosenbaum C. Prediction of in vivo cytotoxicity of chemotherapeutic agents by their effect on malignant leukocytes in vitro. Blood 30: 176–187, 1967.PubMedGoogle Scholar
  48. 48.
    Bickis JJ, Henderson IWD, Quastel JH. Biochemical studies of human tumors. Cancer 19: 103–113, 1966.PubMedGoogle Scholar
  49. 49.
    Tannock I. Cell kinetics and chemotherapy: A critical review. Cancer Treat Rep 62: 1117–1133, 1978.PubMedGoogle Scholar
  50. 50.
    Murphy WK, Livingston RB, Ruiz VG, Gercovich FG, George SL, Hart JS, Freireich EJ. Serial labeling index determinations as a determinator of response in human solid tumors. Cancer Res 35: 1438–1444, 1975.PubMedGoogle Scholar
  51. 51.
    Sky-Peck H. Effects of chemotherapy on the incorporation of 3H thymidine into DNA of human neoplastic tissue. Natl Cancer Inst Monogr 34: 197–205, 1971.PubMedGoogle Scholar
  52. 52.
    Livingston RB. Depression of thymidine labeling index in vitro predicts effects of chemotherapy in patients. Proc Am Assoc Cancer Res and ASCO 20: 317, 1979.Google Scholar
  53. 53.
    Tubiana M, Malaise E. Comparison of cell proliferation kinetics in human and experimental tumors: Response to irradiation. Cancer Treat Rep 1887–1895, 1976.Google Scholar
  54. 54.
    Hart JS, George SL, Frei E, Bodey GP, Nickerson RC, Freireich EJ. Prognostic significance of pretreatment proliferative activity in adult acute leukemia. Cancer 39: 1603–1617, 1977.PubMedGoogle Scholar
  55. 55.
    Zittoun R, Bouchard M, Facquet-Danis J, Percie du Sert M, Bousser J. Prediction of response to chemotherapy in acute leukemia. Cancer 35: 507–513, 1975.PubMedGoogle Scholar
  56. 56.
    Crowther D, Beard MEJ, Bateman CJT, Sewell RL. Factors influencing prognosis in adults with acute myelogenous leukemia. Br J Cancer 32: 456–464, 1975.PubMedGoogle Scholar
  57. 57.
    Wolberg WH, Ansfield FL. The relation of thymidine labeling index in human tumors in vitro to the effectiveness of 5FU. Cancer Res 31: 448–450, 1971.PubMedGoogle Scholar
  58. 58.
    Sulkes A, Livingston R, Taylor G. Pretreatment labeling index in breast cancer as a predictor of response to combination chemotherapy. Proc Am Assoc Cancer Res and ASCO 17: 59, 1976.Google Scholar
  59. 59.
    Thirwell MP, Mansell PWA. A correlation of clinical response with in vitro prechemotherapy labeling index percent in human solid tumors. Proc Am Assoc Cancer Res and ASCO 17: 307, 1976.Google Scholar
  60. 60.
    Nakata Y, Bader JP. The uptake of nucleosides by cells in culture II inhibition by 2-mercapto-1(β-4-pyridethyl)-benzimidazole. Biochim Biophy Acta 190: 250–256, 1969.Google Scholar
  61. 61.
    Raich PC. Prediction of therapeutic response in acute leukemia to drug decreased uptake of tritiated thymidine into leukemic cells. Lancet 1: 74–76, 1978.PubMedGoogle Scholar
  62. 62.
    Steel GG. Cell kinetics and cell survival. In Medical Oncology Medical Aspects of Malignant Disease, Bagshawek D (ed.). Oxford: Blackwell, 1975, pp. 49–66.Google Scholar
  63. 63.
    McDonald GO, Mclver JM, Llamas AJ, Sky-Peck HH. Tumor cytotoxicity: Quantitative changes in DNA synthesis as an indicator. Arch Surg 92: 541–547, 1966.PubMedGoogle Scholar
  64. 64.
    Fjelde A. Human tumor cells in tissue culture. Cancer 8: 845–851, 1955.PubMedGoogle Scholar
  65. 65.
    Berry RJ, Laing AH, Wells J. Fresh explant culture of human tumors in vitro and the assessment of sensitivity to cytotoxic chemotherapy. Br J Cancer 31: 218–227, 1975.PubMedGoogle Scholar
  66. 66.
    Fuskova T, Fuska J, Ivanitskaya LP, Makwkho LV. Different sensitivity to antibiotics of the established intermittent in vitro—in vivo tumor cell line in comparison with primary culture. Neoplasma 24: 239–242, 1977.PubMedGoogle Scholar
  67. 67.
    Pike BL, Robinson WA. Human bone marrow colony growth in agar-gel. J Cell Physiol 76: 77–81, 1970.PubMedGoogle Scholar
  68. 68.
    Metcalf D. In vitro cloning techniques for hematopoietic cells: Clinical applications. Ann Intern Med 87: 483–488, 1977.PubMedGoogle Scholar
  69. 69.
    Bruce WR, Meeker BE, Valeriote FA. Comparison of the sensitivity of normal and transplanted lymphoma colony forming cells to chemotherapeutic agents administered in vivo. J Natl Cancer Inst 37: 233–245, 1966.PubMedGoogle Scholar
  70. 70.
    Wilcox WS, Griswold DP, Laster WR, Schabel FM, Skipper HF. Experimental evaluation of potential anticancer agents. XVII. Kinetics of growth and regression after treatment of certain solid tumors. Cancer Chemother Rep 47: 27–39, 1965.PubMedGoogle Scholar
  71. 71.
    Brown CH, Carbone PP. In vitro growth of normal and leukemic human bone marrow. J Natl Cancer Inst 46: 989–1000, 1971.PubMedGoogle Scholar
  72. 72.
    Park CH, Bergsagel DE, McCulloch EA. Mouse myeloma tumor stem cells: A primary cell culture assay. J Natl Cancer Inst 46: 411–422, 1971.PubMedGoogle Scholar
  73. 73.
    McAllister RM, Reed G. Colony growth in agar of cells from neoplastic and nonneoplastic tissues of children. Pediat Res 2: 356–360, 1968.PubMedGoogle Scholar
  74. 74.
    Altman AJ, Grussi FG, Rierden WJ, Bachner RL. Growth of rhabdomyosarcoma colonies from pleural fluids. Cancer Res 35: 1809–1812, 1975.Google Scholar
  75. 75.
    Hamburger AW, Salmon SE, Kim MB, Trent JM, Soehnlen BJ, Alberts DS, Schmidt HJ. Direct cloning of human ovarian carcinoma cell in agar. Cancer Res 38: 3438–3444, 1978.PubMedGoogle Scholar
  76. 76.
    Hamburger AW, Salmon SE. Primary bioassay of human tumor stem cells. Science 197: 461–463, 1977.PubMedGoogle Scholar
  77. 77.
    Hamburger A, Salmon SE. Primary bioassay of human myeloma stem cells. J Clin Invest 60: 846–854, 1977.PubMedGoogle Scholar
  78. 78.
    Costachel O, Fadei L, Badea E. Tumor cell suspension culture on nonadhesive substratum. Z Krebsforsch 72: 24–31, 1969.PubMedGoogle Scholar
  79. 79.
    Von Hoff DD, Harris GJ, Johnson G, Gaubiger D. Initial experience with the human tumor stem cell assay system: Potentials and problems. In Human Tumor Cloning, Salmon SE (ed.). New York: Alan Liss (in press).Google Scholar
  80. 80.
    Salmon SE, Buick RM. Preparation of permanent slides of soft agar colonies of hematopoietic and tumor stem cells. Cancer Res 39: 1133–1136, 1979.PubMedGoogle Scholar
  81. 81.
    Harris GJ, Zeagler J, Hode KA, Casper J, Von Hoff DD. Ultrastructural analysis of colonies growing in a human tumor cloning system. Cancer (in press).Google Scholar
  82. 82.
    Buick RN, Stanisic TH, Fry SE, Salmon SE, Trent JM, Krasovich P. Development of an agar/methyl cellulose clonogenic assay for progenitor cells in transitional cell carcinoma of the bladder. Cancer Res 39: 5051–5056, 1979.PubMedGoogle Scholar
  83. 83.
    Von Hoff DD. New leads from the laboratory for treating testicular cancer. In Therapeutic Progress in Ovarian Cancer, Testicular Cancer and Sarcomas. The Hague: Martinus Nijhoff, 1980, p. 225.Google Scholar
  84. 84.
    Leibovitz A. In Human Tumor Cells in Vitro, Fogh J (ed.). New York: Plenum, 1975, pp. 23–50.Google Scholar
  85. 85.
    Mavligit GM, Hersh EM, McBride CM. Lymphocyte blastogenic responses to autochthonous viable and nonviable human tumor cells. J Natl Cancer Inst 51: 337–343, 1973.PubMedGoogle Scholar
  86. 86.
    Mattern J, Kaufmann M, Wayss K, Volm M. Studies on the drug sensitivity of short term cultured tumour cell suspensions. In Human Tumors in Short Term Culture, Dendy PP (ed.). New York: Academic Press, 1976, pp. 301–310.Google Scholar
  87. 87.
    Pretlow TG, Jones CM, Pretlow TP. Separation of tumor cells by density gradient centrifugation: Recent work with human tumors and a discussion of the kind of quantitation needed in cell separation experiments. Biophys Chem 5: 99–106, 1976.PubMedGoogle Scholar
  88. 88.
    Rockwell S. In vivo—in vitro tumor systems: New models for studying the response of tumors to therapy. Lab Anim Sci 27: 831–851, 1977.PubMedGoogle Scholar
  89. 89.
    Daniels A, Daniels J, Luck EE. Agarose matrix and enzyme disaggregation improve efficiency of the soft agar chemosensitivity test. Proc Am Assoc Cancer Res and ASCO 22: 155, 1981.Google Scholar
  90. 90.
    Van Wezel AL, Van Hemert PA, Parisiur W, Cucakovich NB, Macmarine HG. Improved cell dispersal method by low temperature incubation of tissue in trypsin-citrate solution. Appl Microbiol 24: 506–507, 1972.PubMedGoogle Scholar
  91. 91.
    Pretlow TG, Brattain MG, Kreisberg JL. Separation and characterization of epithelial cells from prostates and prostatic carcinoma: A review. Cancer Treat Rep 61: 156–159, 1977.Google Scholar
  92. 92.
    Brattain MG, Pretlow TP, Pretlow TG. Cell fractionation of large bowel cancer. Cancer 40: 2479–2480, 1977.PubMedGoogle Scholar
  93. 93.
    Kimball PM, Brattain MG, Pitts AM. A soft agar procedure measuring growth of human colonic carcinoma. Br J Cancer 37: 1015–1019, 1978.PubMedGoogle Scholar
  94. 94.
    Slocum HK, Pavelic ZP, Rustum YM, Creaven PJ, Karakousic C, Takita H, Grecow R. Characterization of cells obtained by medical and enzymatic means from human melanoma and sarcoma and lung tumors. Cancer Res 41: 1428–1434, 1981.PubMedGoogle Scholar
  95. 95.
    Freshney RI. Tumor cells disaggregated in collagenase. Lancet 2: 488–489, 1972.PubMedGoogle Scholar
  96. 96.
    Hodges GM. An overview of tissue culture procedures in tumor biopsy studies. In Human Tumors in Short Term Culture, Dendy PP (ed.). New York: Academic Press, 1976, pp. 3–14.Google Scholar
  97. 97.
    Ham RG. Unique requirements of clonal growth. J Natl Cancer Inst 53: 1459–1463, 1974.PubMedGoogle Scholar
  98. 98.
    Pretlow TG, Weiss EE, Zettergres JG. Problems connected with the separation of different kinds of cells. Int Rev Exp Pathol 14: 91–205, 1975.PubMedGoogle Scholar
  99. 99.
    Salmon SW, Hamburger AW, Soehnlen BS, Durie BGM, Alberts DS, Moon TS. Quantitations of differential sensitivity of human tumor stem cells to anticancer drugs. N Engl J Med 298: 1321–1327, 1978.PubMedGoogle Scholar
  100. 100.
    Salmon SW, Soehnlen BJ, Durie BGM, Alberts DS, Meyskens FL, Chen HSG, Moon TE. Clinical correlations of drug sensitivity in tumor stem cell assay. Proc Amer Assoc Cancer Res and ASCO 20: 340, 1979.Google Scholar
  101. 101.
    Von Hoff DD, Cowan JD, Harris G, Reisdorf G. Human tumor cloning: Feasibility and clinical correlations. Cancer Chemother Pharmacol 6: 265–271, 1981.Google Scholar
  102. 102.
    Kern DH, Campbell MA, Worth GD, Morton DL. Cloning efficiencies and drug sensitivities of freshly prepared suspensions, cryopreserved cells and cell lines derived from human solid tumors. Proc Amer Assoc Cancer Res and ASCO 22: 69, 1981.Google Scholar
  103. 103.
    Von Hoff DD, Casper J, Bradley E, Trent JM, Hodach A, Reichert C, Makuch R, Altman A. Direct cloning of human neuroblastoma cells in soft agar culture. Cancer Res 40: 3591–3597, 1980.Google Scholar
  104. 104.
    Mattox DE, Von Hoff DD. In vitro stem cell assay in head and neck squamous carcinoma. Ann Surg (in press).Google Scholar
  105. 105.
    Pollard EB, Tio F, Whitecar JP, Coltman CA Jr, Von Hoff DD. Utilization of a soft agar system to monitor for marrow involvement with small cell carcinoma of the lung. Proc Am Assoc Cancer Res and ASCO 21: 192, 1980.Google Scholar
  106. 106.
    Von Hoff DD. Clinical correlations of drug sensitivity in tumor stem cell assay. Proc Am Assoc Cancer Res and ASCO 21: 134, 1980.Google Scholar
  107. 107.
    Von Hoff DD, Page C, Harris G, Clark G, Cowan J, Coltman CA. Prospective clinical trial of a human tumor cloning system. Proc Am Assoc Cancer Res and ASCO 22: 154, 1980.Google Scholar
  108. 108.
    Alberts DS, Leigh S, Surwit EA, Serokman R, Moon TE, Salmon SE. Improved survival of patients with relapsing ovarian cancer treated on the basis of drug selection following human tumor clonogenic assay. In Human Tumor Cloning, Salmon SE, Trent JM (eds.). New York: Grune & Stratton, 1984, pp. 509–519.Google Scholar
  109. 109.
    Smallwood JA, Morgan GR, Cooper A, Kirkham N, Williams CJ, Whitehouse JMA, Taylor I. Correlations between clonogenicity and prognostic factors in human breast cancer. Br J Surg 71: 109–111, 1984.PubMedGoogle Scholar
  110. 110.
    Mattox DE, Von Hoff DD, Clark GM, Aufdemorte TB. Factors that influence growth of head and neck squamous carcinoma in the soft agar cloning assay. Cancer 53: 1736–1740, 1984.PubMedGoogle Scholar
  111. 111.
    Miller OL, Grover FL, Trinkle JK, Bennet EV, Clark G, Coltman CA, Von Hoff DD. Growth of tumor colonies in soft agar is a prognostic factor for patients with lung cancer. Surg Forum 34: 435–437, 1983.Google Scholar
  112. 112.
    Von Hoff DD, Casper J, Bradley E, Trent JM, Hodach A, Reichert CH, Makuch R, Altman A. Direct cloning of human neuroblastoma cells in soft agar culture. Cancer Res 40: 3591–3597, 1980.Google Scholar
  113. 113.
    Salmon SE, Alberts D, Meyskens F, Durie B, Jones S, Soehnler B, Young L. A new concept: In vitro trial with the human tumor stem cell assay (HTSCA). Proc Am Assoc Cancer Res and ASCO 21: 329, 1980.Google Scholar
  114. 114.
    Von Hoff DD, Coltman CA Jr, Forseth B, Murray F. Activity of mitoxantrone in a human tumor cloning system: Leads for phase II trials in man. Cancer Res (in press).Google Scholar
  115. 115.
    Von Hoff DD, Gutterman J, Portnoy B, Coltman CA. Human tumor cloning system as a bioassay for interferon. Cancer Chemother and Pharm (in press).Google Scholar
  116. 116.
    Cowan JD, Von Hoff DD. Use of a human tumor stem cell assay to screen retinoids for antineoplastic activity. 20th Interscience Conference on Antimicrobial Agents and Chemotherapy 20: 29, 1980.Google Scholar
  117. 117.
    Cowan JD, Coltman CA Jr, Von Hoff DD. Use of the human tumor cloning system to evaluate cytotoxic activity of misonidazole. Proc Am Assoc Cancer Res and ASCO 22: 233, 1981.Google Scholar
  118. 118.
    Von Hoff DD, Coltman CA Jr, Forseth B. Activity of 9–10 anthracenedicarboxaldehyde bis((4,5-dihydro-1H-imidazol-2-yl)hydrozone) dihydrochloride (CL 216,942) in a human tumor cloning system: Leads for phase II trials in man. Cancer Chemother and Pharm (in press).Google Scholar
  119. 119.
    Slocum HK, Pavelic ZP, Rustum YM, Greco WR, Karakousis C, Tokita H, Creaven PJ. Is there anatomical segregation of important cell populations in solid human tumors? Proc Am Assoc Cancer Res and ASCO 22: 154, 1981.Google Scholar
  120. 120.
    Cowan JD, McCracken JD, Von Hoff DD. Multiple sample drug sensitivity concordance in the human tumor cloning system. Proc Am Assoc Cancer Res and ASCO 22: 350, 1981.Google Scholar
  121. 121.
    Mavligit GM, Barsales PB, Gutterman JU, Mackay V, Hersh EM. A rapid method for establishing short term primary cultures of human tumor cells from fresh tumor biopsies. Proc Soc Exper Biol Med 150: 597–601, 1975.Google Scholar
  122. 122.
    Wicha MS, Liotta LA, Kidwell WR. Effects of free fatty acids on the growth of normal and neoplastic rat mammary epithelial cells. Cancer Res 39: 426–435, 1979.PubMedGoogle Scholar
  123. 123.
    Weisenthal LM, Ruddon RW. Catabolism of nuclear proteins in control and phytohemag-glutinin-stimulated human lymphocytes, leukemic leukocytes, and Burkitt’s lymphoma cells. Cancer Res 33: 2923–2935, 1973.PubMedGoogle Scholar
  124. 124.
    Williams GM, Weisburger EK, Weisburger JH. Isolation and long term culture of epithelial-like cells from rat liver. Exp Cell Res 60: 106–112, 1971.Google Scholar
  125. 125.
    Bloom BR, Bennett B. Mechanism of a reaction in vitro associated with delayed hypersensitivity. Science 153: 80–82, 1966.PubMedGoogle Scholar
  126. 126.
    Hayashi I, Larner J, Sato G. Hormonal growth control of cells in culture. In Vitro 14: 23–30, 1978.Google Scholar
  127. 127.
    Rizzino A, Sato G. Growth of embryonal carcinoma cells in serum-free medium. Proc Natl Acad Sci USA 75: 1844–1848, 1978.PubMedGoogle Scholar
  128. 128.
    Hutchings SE, Sato GH. Growth and maintenance of Hela cells in serum free medium supplemented with hormones. Proc Natl Acad Sci USA 75: 901–904, 1978.PubMedGoogle Scholar
  129. 129.
    Hamburger AW, White CP, Brown RW. Effect of epidermal growth factor on proliferation of human tumor cells in soft agar. Proc Am Assoc Cancer Res and ASCO 22: 215, 1981.Google Scholar
  130. 130.
    Silver RT, Young RC, Holland JF. Some new aspects of modern cancer chemotherapy. Am J Med 63: 772–787, 1977.PubMedGoogle Scholar
  131. 131.
    Valeriote FA, Edelstein MB. The role of cell kinetics in cancer chemotherapy. Semin Oncol 4: 217–226, 1977.PubMedGoogle Scholar
  132. 132.
    Wheeler TLK, Dendy PP, Dawson A. Assessment of an in vitro screening test of cytotoxic agents in the treatment of advanced malignant disease. Oncology 30: 362–376, 1974.PubMedGoogle Scholar
  133. 133.
    Kornblitz PL, Szypko PE. Variations in response of human brain tumors to BCNU in vitro. J Neurosurg 48: 580–586, 1978.Google Scholar
  134. 134.
    Shackney SE, McCormick GW, Cuchural GJ. Growth rate patterns of solid tumors and their relation to responsiveness to therapy. Ann Int Med 89: 107–121, 1978.PubMedGoogle Scholar

Copyright information

© Martinus Nijhoff Publishing, Boston 1987

Authors and Affiliations

  • John D. Cowan
  • Daniel D. von Hoff

There are no affiliations available

Personalised recommendations